Work

TRPC6 N338S is a gain-of-function mutant identified in patient with doxorubicin-induced cardiotoxicity

Year: 2022

Type: article

Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

DOI: 10.1016/j.bbadis.2022.166505

Authors: Tong Lu, Xiaojing Sun, Brian M. Necela, Hon-Chi Lee, Nadine Norton

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)

Language: English

Topic: Chemotherapy-induced cardiotoxicity and mitigation

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, National Heart, Lung, and Blood Institute

Awards: Characterization of TRPC6 to predict and prevent chemotherapy-related heart failure, Individualized medicine to predict and prevent chemotherapy-related heart failure

OpenAlex ID: W4286751363

FWCI: 0.87

Cites: 46

Cited by: 10

Related to: 10